



Universiteit
Leiden
The Netherlands

Added predictive value of female-specific factors and psychosocial factors for the risk of stroke in women under 50

Os, H.J.A. van; Kanning, J.P.; Ferrari, M.D.; Bonten, T.N.; Kist, J.M.; Vos, H.M.M.; ... ;
Wermer, M.J.H.

Citation

Os, H. J. A. van, Kanning, J. P., Ferrari, M. D., Bonten, T. N., Kist, J. M., Vos, H. M. M., ...
Wermer, M. J. H. (2023). Added predictive value of female-specific factors and
psychosocial factors for the risk of stroke in women under 50. *Neurology*, 101(8), e805-
e814. doi:10.1212/WNL.0000000000207513

Version: Publisher's Version
License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3704875>

Note: To cite this publication please use the final published version (if applicable).

Added Predictive Value of Female-Specific Factors and Psychosocial Factors for the Risk of Stroke in Women Under 50

Hendrikus J.A. van Os, MD, PhD, Jos P. Kanning, MSc, Michel D. Ferrari, MD, PhD, Tobias N. Bonten, MD, PhD, Janet M. Kist, MD, Hedwig M.M. Vos, MD, PhD, Rimke C. Vos, PhD, Hein Putter, PhD, Rolf H.H. Groenwold, MD, PhD, and Marieke J.H. Wermer, PhD

Correspondence

Dr. van Os
h.j.a.van_os@lumc.nl

Neurology® 2023;101:e805-e814. doi:10.1212/WNL.0000000000207513

Abstract

Background and Objectives

Female-specific factors and psychosocial factors may be important in the prediction of stroke but are not included in prediction models that are currently used. We investigated whether addition of these factors would improve the performance of prediction models for the risk of stroke in women younger than 50 years.

Methods

We used data from the Stichting Informatievoorziening voor Zorg en Onderzoek, population-based, primary care database of women aged 20–49 years without a history of cardiovascular disease. Analyses were stratified by 10-year age intervals at cohort entry. Cox proportional hazards models to predict stroke risk were developed, including traditional cardiovascular factors, and compared with models that additionally included female-specific and psychosocial factors. We compared the risk models using the *c*-statistic and slope of the calibration curve at a follow-up of 10 years. We developed an age-specific stroke risk prediction tool that may help communicating the risk of stroke in clinical practice.

Results

We included 409,026 women with a total of 3,990,185 person-years of follow-up. Stroke occurred in 2,751 women (incidence rate 6.9 [95% CI 6.6–7.2] per 10,000 person-years). Models with only traditional cardiovascular factors performed poorly to moderately in all age groups: 20–29 years: *c*-statistic: 0.617 (95% CI 0.592–0.639); 30–39 years: *c*-statistic: 0.615 (95% CI 0.596–0.634); and 40–49 years: *c*-statistic: 0.585 (95% CI 0.573–0.597). After adding the female-specific and psychosocial risk factors to the reference models, the model discrimination increased moderately, especially in the age groups 30–39 (Δc -statistic: 0.019) and 40–49 years (Δc -statistic: 0.029) compared with the reference models, respectively.

Discussion

The addition of female-specific factors and psychosocial risk factors improves the discriminatory performance of prediction models for stroke in women younger than 50 years.

MORE ONLINE

 CME Course
[NPub.org/cmelist](https://www.npub.org/cmelist)

Glossary

aHR = adjusted HR; **ATC** = Anatomical Therapeutic Chemical; **EHR** = electronic health record; **HR** = hazard ratio; **ICD-9** = *International Classification of Diseases, Ninth Revision*; **ICD-10** = *International Classification of Diseases, Tenth Revision*; **ICPC** = International Classification of Primary Care; **SCORE2** = Systematic COronary Risk Evaluation 2; **STIZON** = Stichting Informatievoorziening voor Zorg en Onderzoek.

Introduction

Stroke is one of the leading causes of death and disability globally.¹ A decision to start preventive treatment depends first of all on the absolute risk of cardiovascular disease, including stroke and myocardial infarction, over a period of 10 years. The current European guidelines recommend the use of the Systematic COronary Risk Evaluation 2 (SCORE2) for estimating cardiovascular risk in the general population.^{2,3} This prediction model includes only traditional cardiovascular factors such as age, diabetes, hypertension, cholesterol, and smoking. However, there is increasing evidence that female-specific risk factors of stroke and other cardiovascular diseases, such as migraine, hormonal disorders, and preeclampsia, are also important. In a systematic review of cardiovascular risk models in the general population, only 2 of 160 (1.3%) studies had used female-specific factors.⁴ Both studies, and an additional one published a year later, concluded that inclusion of female-specific risk factors did not result in the improvement of model discrimination and reclassification.^{5,6} However, the primary outcome measure of these studies was a combination of several major cardiovascular events, including myocardial infarction. Female-specific factors, however, primarily increase the risk of stroke.^{7,8} Moreover, these studies included mainly postmenopausal women, while female-specific factors such as migraine and oral contraceptives increase the risk of stroke especially at reproductive age.^{9,10} Psychosocial factors, such as low socioeconomic status and depression, have also been found to increase the risk of stroke to a greater extent in women than in men.¹¹⁻¹⁴ However, their added value has hardly been assessed in prediction models for stroke.⁴ The aim of this study was, therefore, to investigate whether female-specific factors and psychosocial factors would improve the performance of prediction models for the risk of stroke in women younger than 50 years, compared with models with traditional cardiovascular factors alone.

Methods

Data Source

We used data from the Stichting Informatievoorziening voor Zorg en Onderzoek (STIZON) database, which directly retrieves data from electronic health records (EHRs) of a large number of primary care providers throughout the Netherlands and covers approximately 20% of the Dutch population.¹⁵ From the STIZON dataset, we selected only women from general practice centers, which were situated in catchment areas of hospitals participating in the STIZON

network. This allowed for linkage of hospital *International Classification of Diseases, Ninth Revision (ICD-9)* and *International Classification of Diseases, Tenth Revision (ICD-10)* diagnoses to primary care data. The STIZON dataset contains International Classification of Primary Care (ICPC) diagnosis codes for clinical entities and medication prescriptions according to the Anatomical Therapeutic Chemical (ATC) Classification System from primary care pharmacies.^{16,17} ICD-9 and ICD-10 codes were present for all in-hospital diagnoses that occurred during follow-up, while ICPC diagnosis codes were in principle available since birth. Inclusion criteria were female sex (as determined by registration in the primary care EHR), age of 20–49 years, and subscription to a STIZON general practice center between January 1, 2007, and December 31, 2020, for minimally 1 year. The first year of subscription was necessary because we defined this as a 1-year run-in period to assess predictor values such as prescribed medication or assessments of vital parameters. Exclusion criteria were a history of cardiovascular disease before baseline, including myocardial infarction, stroke, angina pectoris, peripheral artery disease, heart failure, and transient ischemic attack. Follow-up time started at the end of the 1-year run-in period, which was on January 1, 2008, or on the first general practice center subscription to the STIZON network after this date. Women were censored at the earliest date of the diagnosis of a major adverse cardiovascular event, death, deregistration with any practice connected to the STIZON network, or last upload of computerized data to the STIZON database (December 31, 2020).

Standard Protocol Approvals, Registrations, and Patient Consents

The ethics review board has provided a statement that this study was not subject to ethics review according to the Medical Research Involving Human Subjects Act (World Meteorological Organization).

Outcome Definition

The primary outcome of our study was fatal and nonfatal stroke, defined as the presence of an ICD-9, ICD-10, or ICPC code for overall stroke or ischemic or hemorrhagic stroke subtypes specifically (eTable 1, links.lww.com/WNL/C986).

Traditional Cardiovascular Factors

Data on the following traditional cardiovascular factors were included for this study: age, smoking (defined as current or former tobacco use), and either an ICD-9, ICD-10, or ICPC diagnosis code or condition-specific ATC medication prescription code for hyperlipidemia, hypertension, and diabetes

mellitus (eTable 1, links.lww.com/WNL/C986). We did not use biomarker measurements such as serum cholesterol, blood pressure, and blood glucose because these measurements were missing in most (>80%) of the women in our research population. The measurement data are likely not missing at random, and in combination with the large extent of missing information, imputation would probably lead to biased imputations.¹⁸ For binary factors such as smoking, in case of absence of the registration of smoking status in the EHR, it was not possible to distinguish between actual and unknown smoking status. Therefore, we considered the absence of the registration of smoking status as the absence of smoking, implying the imputation of zero. Risk factor information was assessed at the start of follow-up and at the end of the 1-year run-in period.

Female-Specific Factors

The following female-specific factors for stroke were included based on previous literature: migraine, gestational diabetes, preeclampsia, preterm birth (0 vs ≥ 1), miscarriage (0 vs ≥ 1), stillbirth (0 vs ≥ 1), menstrual irregularity or primary ovarian insufficiency, female infertility (unspecified), hysterectomy in medical history, poor fetal growth or small for gestational age of a woman's child, complications during birth (postpartum hemorrhage, intrapartum hemorrhage, umbilical cord complications), hormonal replacement therapy, and combined hormonal contraceptive use.¹⁹⁻²¹ A female-specific factor was considered present when either an ICD-10, ICD-9, or ICPC diagnosis code or condition-specific ATC medication prescription code was present. The female-specific factors menstrual irregularity and primary ovarian insufficiency were clustered into menstrual irregularity of any cause because primary ovarian insufficiency is a main cause for menstrual irregularity.²² The definition of female-specific factors based on these codes is summarized in eTable 1 (links.lww.com/WNL/C986).

Psychosocial Factors

Based on the literature, we selected the following psychosocial factors.¹¹⁻¹⁴ Socioeconomic status score was derived from the first 4 postal code digits, using data from the Netherlands Institute for Social Research as a standardized measure based on income, education, and occupation of the inhabitants.²³ A history of depression or psychotic disorders was defined by either an ICD-10, ICD-9 or ICPC diagnosis code or ATC code for antidepressant or antipsychotic drug prescriptions.

Statistical Analysis

We developed multivariable Cox proportional hazards regression models for prediction of the risk of stroke. Because previous literature showed significant age-dependent effects of female-specific factors on risk of stroke,^{24,25} we stratified all analyses by three 10-year intervals using age at baseline of 20–29, 30–39, and 40–49 years to study potential age-dependent effects of female-specific and psychosocial factors. We used a rolling age at baseline with 10-year age intervals. This means, for example, that a woman who was 25 years of

age in 2008 could also have contributed to the 30–39 years at baseline interval because follow-up data were available for maximally 13 years. We assessed the potential added value of female-specific factors regarding the prediction of risk of stroke using a stepwise approach. First, female-specific factors with a prevalence of less than 0.5% in the overall research cohort were excluded. Second, we assessed both the univariate association of each female-specific factor with risk of stroke and the association between female-specific factors and risk of stroke independent of traditional cardiovascular factors by developing different models with 1 female-specific factor together with the 5 traditional cardiovascular factors. For all 3 age-based strata, we reported both the hazard ratio (HR), adjusted HR (aHR), and 95% CI of each female-specific factor and model discrimination and change in model discrimination that resulted from including each female-specific factor separately. Third, all female-specific and psychosocial factors that occurred in more than 0.5% of the overall research cohort were included in final models per age stratum (Table 2).

We compared model performance using the selection of traditional cardiovascular, female-specific, and psychosocial factors from step 3, compared with reference models with traditional cardiovascular factors alone. Model performance was assessed through both model discrimination (*c*-statistic) and calibration (calibration curve slope, assessed at 10 years of follow-up). Furthermore, we expressed change in *c*-statistic between reference models and models including female-specific and psychosocial factors as difference with the reference model relative to the full scale, which follows from the equation below.

$$\frac{(c\text{-statistic (new model)} - c\text{-statistic (reference model)})}{(c\text{-statistic (reference model)} - 0.5)}$$

Performance metrics were internally validated using 100 bootstraps and corrected for optimism using a previously validated method (Harrell bias correction).²⁶ We repeated the bootstrap procedure 50 times and used the mean values and variances of the corresponding bootstrap distribution to derive the point and interval estimates of the performance metrics. Empirical confidence intervals were derived by repeating the bootstrap procedure 50 times. We did not take noncardiovascular death into account as a competing risk because we assessed a cohort of young women at a maximum of 49 years at baseline. In this population, the cumulative incidence of noncardiovascular death will be very small compared with the entire population, limiting the competing risk effect on the estimation of the risk of stroke. Because our cohort consists of relatively young women, the absolute 10-year risk of stroke will be predominantly less than 1%, which is the lower bound of the moderate risk category according to the European Society of Cardiology Prevention guideline for cardiovascular disease.² Consequently, no meaningful absolute risk cutoff is available to use for the assessment of model performance using, for example, the categorical net reclassification index.²⁷

To facilitate the interpretation of the absolute 10-year risk predictions of (non)fatal stroke from our models, we have developed a novel tool based on the previously published cardiovascular risk age tool.²⁸ The principle of this tool is that (1) as a reference, for each age, the absolute risk of stroke is calculated for women without any traditional cardiovascular, female-specific, and psychosocial risk factors; (2) For women at a certain age and 1 or more risk factors, the absolute 10-year risk is compared with the reference to find the corresponding “stroke risk age,” which may be substantially higher than the actual age. We will present 2 clinical vignettes to illustrate the clinical utility of our stroke risk age tool.

Data Availability

Because of the sensitive nature of the data collected for this study, data will need to be requested from a third party (STIZON).

Results

We included 409,026 women, aged 20–49 years, with no history of cardiovascular disease at baseline with a total of 3,990,185 person-years of follow-up. Stroke occurred in 2,751 women over a median of 11 years. The overall incidence rate of stroke was 6.9 (95% CI 6.6–7.2) per 10,000 person-years, increasing exponentially in the 3 age groups (Table 1). The prevalence of traditional cardiovascular factors at baseline increased significantly by age group. Hypertension was the most common traditional cardiovascular risk factor (12% in women aged 40–49 years at baseline) and complications during childbirth the most frequent female-specific risk factor (11% in women aged 30–39 years at baseline). Female-specific factors that occurred in less than 0.5% of the entire population were polycystic ovary syndrome, gestational diabetes, and history of hysterectomy (Table 2).

The female-specific and psychosocial factors that were independently associated with stroke as traditional cardiovascular factors were as follows: in women aged 20–29 years: irregular menstruation for any cause and complications during childbirth and hormonal replacement therapy; in women aged 30–39 years: migraine, preeclampsia, complications during childbirth, combined hormonal contraceptive use, socioeconomic status score, and depression; and in women aged 40–49 years: combined hormonal contraceptive use, socioeconomic status score, depression, and psychotic disorder (eTable 2, links.lww.com/WNL/C986).

Model performance of models including only traditional cardiovascular factors was poor to moderate in all age groups: 20–29 years: *c*-statistic: 0.617 (95% CI 0.592–0.639); 30–39 years: *c*-statistic: 0.615 (95% CI 0.596–0.634); and 40–49 years: *c*-statistic of 0.585 (95% CI: 0.573–0.597). The slopes of the calibration curves of the reference models in the 3 age groups were good: 20–29 years: 0.949 (95% CI 0.894–0.978); 30–39 years: 0.974 (95% CI 0.951–0.995); and 40–49 years: 0.984 (95% CI 0.962–1.000; Table 3). The addition of female-specific risk factors to the reference models led to a moderate improvement of model discrimination, especially in the 40–49 years age group (Δc -statistic: 0.016 compared with that in reference model, 18.8% difference with the reference model relative to full scale). The addition of psychosocial factors social status score and history of depression further increased the discriminatory performance in the 30–39 and 40–49 years age group (Δc -statistic: 0.019 and 0.029, respectively, compared with that in reference models; and a 16.5% and 34.1% difference, respectively, compared with the reference model relative to the full scale of the *c*-statistic, Table 3). The absolute 10-year risks of stroke predicted by the models combining traditional cardiovascular, female-specific, and psychosocial factors were generally low but increased substantially across age strata (Figure 1).

Figure 2 shows calibration curves of the 3 models containing traditional cardiovascular, female-specific, and psychosocial risk factors. Hazard ratios of all predictors of the 3 models are summarized in eTable 1 (links.lww.com/WNL/C986).

Finally, we present 2 illustrative clinical vignettes based on the prediction models from this study. First, a 33-year-old woman with a history of migraine, who smokes and uses combined hormonal contraceptives, has a mean predicted absolute 10-year risk of stroke of 0.7% (95% CI 0.4%–1.1%) according to our model. According to our stroke risk age tool, this risk is comparable with that of a 43-year-old woman without any predefined risk factors other than age. Second, a 40-year-old woman with a history of depression and hypertension using combined hormonal contraceptives has a mean predicted absolute 10-year risk of stroke of 1.1% (95% CI 0.8%–1.4%) in our model, which is similar to the risk of stroke of a 48-year-old woman without any predefined risk factors according to the stroke risk age tool (Figure 3).

Table 1 Incidence Rate of Stroke per Age Group

Age group (years of age at baseline)	Patients (n)	Total follow-up (y)	Events (n)	Incidence rate per 10,000 person years (95% CI)
20–29	128,885	1,145,403	254	2.2 (1.9–2.5)
30–39	136,708	1,340,917	705	5.3 (4.9–5.6)
40–49	143,433	1,503,865	1,792	11.9 (11.4–12.5)
Total	409,026	3,990,185	2,751	6.9 (6.6–7.2)

Table 2 Baseline Characteristics for Women in 3 Age Groups Between 20 and 49 Years at Baseline With and Without Stroke

Groups	Baseline characteristic	20–29 y ^a		30–39 y		40–49 y	
		Stroke (n = 254)	No stroke (n = 128,631)	Stroke (n = 705)	No stroke (n = 136,003)	Stroke (n = 1,792)	No stroke (n = 141,641)
	Age, mean (±SD)	25.6 (2.6)	24.6 (2.9)	36.4 (3.0)	35.1 (3.2)	45.5 (3.1)	44.9 (3.1)
Cardiovascular risk factors, n (%)	Smoking (ever)	<10 (<3.9)	1,345 (1.0)	22 (3.1)	2,000 (1.5)	87 (4.9)	3,304 (2.3)
	Hyperlipidemia	<10 (<3.9)	346 (0.3)	22 (3.1)	1,022 (0.8)	108 (6.0)	3,666 (2.6)
	Hypertension	13 (5.1)	3,997 (3.1)	73 (10.4)	5,893 (4.3)	355 (19.8)	15,044 (10.6)
	Diabetes mellitus	<10 (<3.9)	556 (0.4)	15 (2.1)	1,176 (0.9)	67 (3.7)	2,478 (1.7)
Women-specific risk factors, n (%)	Migraine	<10 (<3.9)	3,678 (2.9)	47 (6.7)	5,116 (3.8)	106 (5.9)	7,316 (5.2)
	Gestational diabetes	<10 (<3.9)	216 (0.2)	<10 (1.4)	734 (0.5)	<10 (0.6)	285 (0.2)
	Preeclampsia	<10 (<3.9)	556 (0.4)	20 (2.8)	1,933 (1.4)	<10 (0.6)	645 (0.5)
	Preterm birth ≥1	<10 (<3.9)	743 (0.6)	21 (2.9)	2,574 (1.9)	10 (0.6)	1,214 (0.9)
	Abortion ≥1	<10 (<3.9)	2,356 (1.8)	32 (4.5)	5,617 (4.1)	34 (1.9)	2,518 (1.8)
	Menstrual irregularity	12 (4.7)	3,182 (2.5)	28 (3.9)	4,159 (3.1)	85 (4.7)	5,859 (4.1)
	Infertility	<10 (<3.9)	996 (0.8)	11 (1.6)	3,459 (2.5)	16 (0.9)	1,376 (1.0)
	Hysterectomy	<10 (<3.9)	215 (0.2)	<10 (1.4)	221 (0.2)	<10 (0.6)	239 (0.2)
	Poor fetal growth	<10 (<3.9)	434 (0.3)	<10 (1.4)	1,221 (0.9)	10 (0.6)	525 (0.4)
	Complications during birth	22 (8.7)	4,858 (3.8)	93 (13.2)	14,878 (10.9)	56 (3.1)	5,349 (3.8)
	Hormonal replacement therapy	<10 (<3.9)	283 (0.2)	<10 (1.4)	670 (0.5)	33 (1.8)	1,658 (1.2)
	Combined hormonal contraceptive use	120 (47.2)	59,471 (46.2)	297 (42.1)	46,287 (34.0)	606 (33.8)	35,950 (25.4)
Psychosocial risk factors	Socioeconomic status score, mean (±SD) ^b	0.18 (0.77)	0.19 (0.76)	0.21 (0.77)	0.29 (0.74)	0.24 (0.72)	0.32 (0.68)
	Depression, n (%)	19 (7.5)	6,056 (4.7)	83 (11.8)	10,534 (7.7)	327 (16.3)	15,844 (10.2)
	Psychotic disorder, n (%)	<10 (<3.9)	1,145 (0.9)	<10 (1.4)	1,795 (1.3)	57 (3.2)	2,189 (1.5)

^a Age at baseline.^b The mean socioeconomic status score based on principal component analysis, with higher scores indicating higher socioeconomic status.

Discussion

In this study, we showed (1) that female-specific factors such as migraine, irregular menstruation, complications during childbirth, preeclampsia, hormonal replacement therapy, and combined hormonal contraceptive use and psychosocial risk factors such as social status score and a history of depression or psychotic disorders are associated with an increased risk of stroke in women aged 20–49 years, (2) that this association is independent of that caused by traditional cardiovascular risk factors, and, (3) that associations change across the three 10-year age strata. Moreover, addition of these risk factors to prediction models that include only traditional cardiovascular risk factors increased the predictive performance of models for the prediction of stroke in women aged 20–49 years.

Three studies previously investigated the added value of female-specific risk factors in cardiovascular risk models.^{5,6,29}

In the Women's Health Initiative Observational Study, pregnancy loss, absence of breastfeeding for ≥1 month, and irregular menstruation were independently associated with an increased future risk of cardiovascular events in postmenopausal women.⁶ However, adding these factors to the model only modestly improved the *c*-statistic from 0.726 to 0.730. In a Norwegian study, only preeclampsia remained associated with the risk of cardiovascular events after adjustment for established risk factors (HR 1.60; 95% CI 1.16–2.17).⁵ The addition of pregnancy complication history to the established prediction model led to small improvements in discrimination (*c*-statistic difference 0.004, 95% CI 0.002–0.006) and correct reclassification of events (net reclassification improvement 0.02, 95% CI 0.002–0.05). A Swedish study found that low birth weight of a woman's child was associated with cardiovascular events (aHR 1.68; 95% CI 1.19–2.37).²⁹ The addition of a history of hypertensive disorders during pregnancy or low birth weight of the offspring

Table 3 Performance of Women-Specific Cox Proportional Hazard Models With Different Risk Factor Selections Across the 3 Age Groups

Age range	Risk factor selections	c-statistic (95% CI)	Δ c-statistic ^a	Δ c-statistic ^b	Calibration curve slope (95% CI)
20–29 y	Traditional cardiovascular	0.617 (0.592–0.639)	Ref.	Ref.	0.949 (0.894–0.978)
	Traditional + women specific	0.625 (0.590–0.652)	0.008	6.8%	0.871 (0.801–0.939)
	Traditional + women specific + psychosocial	0.632 (0.606–0.660)	0.015	12.8%	0.868 (0.808–0.920)
30–39 y	Traditional cardiovascular	0.615 (0.596–0.634)	Ref.	Ref.	0.974 (0.951–0.995)
	Traditional + women specific	0.624 (0.604–0.648)	0.009	7.8%	0.957 (0.933–0.976)
	Traditional + women specific + psychosocial	0.634 (0.611–0.658)	0.019	16.5%	0.937 (0.894–0.960)
40–49 y	Traditional cardiovascular	0.585 (0.573–0.597)	Ref.	Ref.	0.984 (0.962–1.000)
	Traditional + women specific	0.601 (0.592–0.610)	0.016	18.8%	0.957 (0.941–0.975)
	Traditional + women specific + psychosocial	0.614 (0.601–0.628)	0.029	34.1%	0.959 (0.943–0.970)

Model performance metrics were optimism corrected using 100 bootstraps and empirical confidence intervals were derived by repeating the bootstrapping procedure 50 times.

^a Difference between c-statistics of reference models (traditional cardiovascular risk factors) and models including women-specific and psychosocial risk factors.


^b Difference between c-statistics expressed as difference with the reference model relative to full scale (c-statistic range of 0.5–1.0).

to the traditional cardiovascular risk factors did not meaningfully improve the 10-year prediction of cardiovascular risk in women aged 50 years or older.

Of importance, all these studies were conducted mainly or exclusively in peri- or postmenopausal women, whereas the stroke risk increasing effect of female-specific risk factors seems to be mainly or only present in young woman. By contrast, our study was conducted in premenopausal women and aimed to determine whether female-specific factors had a potential added predictive value for stroke and whether this differed in different age groups. For example, in the study of Kurth et al.,²⁴ migraine increased the risk of stroke only in women aged 45–49 years, but not in older age. In our study,


migraine was an independent risk factor in women aged 30–39 years at baseline. However, because the median follow-up time was 11 years, this probably corresponds to a relative risk increase of stroke in the mid-40s age range. Moreover, for preeclampsia, there is mainly evidence for an increased risk of stroke during the reproductive age (relative risk 1.81; 95% CI 1.45–2.27), which is consistent with our findings in the age group between 30 and 39 years. However, another study found an increased risk of stroke in women with a history of preeclampsia up to the sixth life decade.²⁵ This finding contrasts with our study, which found no increased risk in women aged 40–49 years. Of interest, we found a strongly increased risk of stroke in women aged 20–29 years who used hormonal replacement therapy. This finding may be confounded by

Figure 1 Absolute 10-Year Risk Predictions of Female-Specific Prediction Models Across 3 Age Ranges



On the x-axis are predicted probabilities from optimism-corrected prediction models including traditional cardiovascular, female-specific, and psychosocial risk factors. Predicted probabilities are divided into bins based on increments 0.1%, and on the y-axis, the fraction of the population within each bin is plotted.

Figure 2 Calibration Plots of Female-Specific Prediction Models Across 3 Age Ranges




Calibration plots show on the y-axis the observed probabilities, and on the x-axis the predicted probabilities at 10 years of follow-up. The 3 models for the different age ranges at baseline contain the traditional cardiovascular, female-specific, and psychosocial factors. For each model, 2 calibration curves are constructed using restricted cubic splines with a Cox proportional hazards model (10 knots). Ideal calibration is represented by a dashed line and the optimism-corrected models by a continuous line.

premature ovarian insufficiency, which itself may be under-reported in the EHR.³⁰

In contrast to these earlier studies, we found an improvement in the discrimination of the stroke prediction models in women aged 30–39 years after adding female-specific and psychosocial factors. This may be explained by a differential effect of female-specific factors on stroke specifically vs general cardiovascular outcomes, the selection of other female-specific factors, the addition of psychosocial factors to our prediction models, or the stratification into three 10-year age groups.

Our study also has limitations. First, there are a number of quality problems with EHR-derived data, particularly the underreporting of clinical conditions.^{31,32} For example, the lifetime prevalence of migraine in women is estimated to be approximately 33%.³³ However, in the Dutch primary care EHR data, on average, migraine is recorded only in 2.5% of the general population.³⁴ In our study, we found an EHR registration for migraine in 4.0% of women younger than 50 years. There are several reasons for the underreporting of migraine. Many patients with migraine do not visit the general practitioner for their migraine,³⁵ and if they do, migraine is

Figure 3 Visualization of the Stroke Risk Age Tool



This figure shows the graph of predicted absolute 10-year risk of stroke for women without any traditional cardiovascular, female-specific, and psychosocial risk factor levels and age increasing from 30 to 65 years and the absolute 10-year risks of women from vignettes 1 and 2 plotted in the same graph.

probably not always accurately reported in the EHR by the general practitioner.³² It is probable that patients who do visit the general practitioner have a more severe migraine phenotype, which is more likely to be recorded in the EHR. Because migraine with a high attack frequency has a relatively stronger relation with the risk of ischemic stroke, in our study, the association between migraine and stroke could be overestimated.³⁴ Not only migraine, but also other factors such as smoking (only 3% of women) were underreported in our data. Moreover, although primary care EHR systems have already been widely used since 1990, the quality of the records has increased in recent decades due to improvements in quality control.³⁵ Therefore, the reporting of female-specific factors related to pregnancy and childbirth may be less accurate in the 40–49 years age group than in younger age groups. For the derivation of our prediction models, however, the underreporting of traditional cardiovascular, female-specific, and psychosocial factors does not necessarily pose a problem. After all, measurement error (including underreporting) in predictors is unlikely to affect the generalizability and transportability of our prediction models if the measurement error is similar in the deployment setting of the models. Therefore, our models should be used within an EHR context; for example, to screen the EHR for young women at an increased risk of stroke.³⁶

Second, our reference models included predictors based on the ICPC, ICD-9, ICD-10, or ATC codes for hypertension, hyperlipidemia, and diabetes, instead of continuous measurements of blood pressure, cholesterol, or serum glucose, which are used in most cardiovascular risk prediction models.³⁶ Not including continuous measurement data in our reference models may have reduced the predictive performance. However, more than 90% of our population lacked measurement data, and the values were probably not missing at random. Therefore, imputation would likely have resulted in biased imputed values.¹⁸

Third, the discriminatory performance of the prediction models in this study is moderate (*c*-statistics of approximately 0.61–0.63) but is comparable with prediction models that have been implemented in clinical practice such as CHA₂DS₂-VASc.³⁷ In addition, because age is by far the most important predictor for the risk of stroke, the restriction of age at baseline to a 10-year range also reduces the *c*-statistic. Furthermore, good model calibration around the absolute risks that are relevant for clinical decisions may be a better indicator for the clinical use of a model compared with model discrimination.³⁸ The calibration of the models derived from the populations of women aged 20–29 and 30–39 at baseline—even after optimism correction—deteriorates for higher predicted probabilities. This can be explained by the fact that in our young population, the absolute event risk is very low. For example, virtually no women aged 30–39 years at baseline have absolute 10-year risks higher than 2%. Although there is no generally accepted absolute risk threshold to guide clinical decisions in this age group, our models are likely able to make a distinction between relatively high vs low absolute risks in this population.

Fourth, the clinical outcome in our study included both ischemic and hemorrhagic stroke subtypes. Female-specific risk factors may have a differential effect on these 2 subtypes. In a meta-analysis, migraine had a larger effect on hemorrhagic (aHR 1.43; 95% CI 1.03–1.99) than on ischemic stroke (aHR 1.29; 95% CI 1.08–1.54).³⁹ From a clinical utility perspective, however, the overall stroke outcome of prediction models may be more practical because in the context of primary prevention, no distinction is made between ischemic and hemorrhagic stroke.²

Fifth, the registration of noncardiovascular death outside the hospital in the primary care EHR is known to be relatively incomplete. However, this problem is likely to be limited due to the relatively small fraction of noncardiovascular deaths in our young population.

Sixth, the EHR data on which our study is based do not contain specific information regarding gender. Therefore, we could not discern between cisgender and transgender and gender-expansive individuals, and it is unclear whether results can be generalized to transgender and gender expansive individuals.

Strengths of our study include the use of the largest dataset to date to study female-specific risk factors in women younger than 50 years and to develop female-specific prediction models. Moreover, in our cohort study, primary care and hospital diagnosis codes were linked. This allowed for a more valid determination of the clinical outcome compared with the use of primary care data alone. Furthermore, by stratifying our population into 10-year age groups, we were able to account for variation in the associations between female-specific risk factors and risk of stroke across the life span.

Although many different prediction models for the risk of cardiovascular events have been developed, female-specific factors or women younger than 40 years are rarely included.⁴⁰ In our study, we aim to fill an important knowledge gap by developing prediction models for stroke risk including female-specific risk factors, specifically in a young population. A challenge in using prediction models for risk of cardiovascular events and stroke in individuals younger than 50 years is that the predicted absolute 10-year risks are generally very low. In our population, these risks were generally lower than 2.5%. The European Society of Cardiology guideline for the prevention of cardiovascular disease recommends preventive medication from an absolute 10-year SCORE2 risk of 2.5% and onward in individuals younger than 50 years.² This, however, does not mean that predicted 10-year risks under 2.5% are irrelevant. The stroke risk age tool developed in this study could help select young women with an absolute risk of stroke that is relatively high due to combinations of female-specific, psychosocial, and modifiable cardiovascular risk factors, compared with women without these factors. Currently, a lack of risk awareness is a major factor contributing to the lack of preventive measures and healthy lifestyle choices among

women.⁴¹ These women could be proactively advised to eliminate modifiable risk factors early in life to prevent cardiovascular events and other diseases such as dementia.^{28,42,43} Moreover, in younger women, female-specific risk factors often precede the occurrence of traditional cardiovascular risk factors—for example, preeclampsia preceding the occurrence of hypertension.⁴⁴

Our models could be used to automatically screen primary care EHRs in a simple, noninvasive, relatively inexpensive way because all risk factors used in our models are based solely on the medical history present in the primary care EHR. Women at an increased risk of stroke could be identified and invited for further screening in primary care practice. Because the quality of routine data is limited, further research is needed to assess the use of EHR-derived models for individual prediction and recommendation of treatment. Future efforts should focus on improving the quality of data recording in the EHR. Based on our results, we advise healthcare professionals—and especially general practitioners—to take female-specific and psychosocial factors into account for the estimation of the risk of stroke and to invest in the quality of registrations of these factors in the EHR. Of importance, it is likely that psychosocial factors “depression” and “psychotic disorders” are at least to some extent indicators for social determinants of health, which could practically not have been retrieved from the EHR. Therefore, in the implementation phase of prediction models that use such indicators, we should invest in education of all end users to prevent any form of stigmatization.

The addition of female-specific and psychosocial risk factors to traditional cardiovascular predictors improves the discriminatory performance of prediction models for women younger than 50 years. Our newly developed stroke risk age tool can help discuss stroke risk in clinical practice.

Study Funding

M.J.H. Wermer was supported by a personal Vidi and Aspasia grant from ZonMw/NWO (91717337) and a Dekker Clinical Established Investigator Grant from the Dutch Heart Foundation (2016T86). Dr. Van Os was funded by a personal Dekker Junior Clinical Scientist Grant (2018T082) and the Innovation Grant (2018T016) from the Dutch Heart Foundation and a ZonMw Gender & Prevention Grant (555003014).

Disclosure

The authors report no relevant disclosures. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

Publication History

Received by *Neurology* August 26, 2022. Accepted in final form April 25, 2023. Submitted and externally peer reviewed. The handling editor was Editor-in-Chief José Merino, MD, MPhil, FAAN.

Appendix Authors

Name	Location	Contribution
Hendrikus J.A. van Os, MD, PhD	Department of Neurology, National eHealth Living Lab, and Department of Public Health & Primary Care/Health Campus The Hague, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
Jos P. Kanning, MSc	Department of Neurology, University Medical Center Utrecht, the Netherlands	Study concept or design; analysis or interpretation of data
Michel D. Ferrari, MD, PhD	Department of Neurology, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content
Tobias N. Bonten, MD, PhD	Department of Public Health & Primary Care/Health Campus The Hague, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content
Janet M. Kist, MD	Department of Public Health & Primary Care/Health Campus The Hague, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content
Hedwig M.M. Vos, MD, PhD	Department of Public Health & Primary Care/Health Campus The Hague, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content
Rimke C. Vos, PhD	Department of Public Health & Primary Care/Health Campus The Hague, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content
Hein Putter, PhD	Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data
Rolf H.H. Groenwold, MD, PhD	Department of Clinical Epidemiology, and Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands	Drafting/revision of the article for content, including medical writing for content; study concept or design
Marieke J.H. Wermer, PhD	Department of Neurology, Leiden University Medical Center; Department of Neurology, University Medical Center Groningen, the Netherlands	Drafting/revision of the article for content, including medical writing for content; study concept or design; and analysis or interpretation of data

References

- Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation*. 2021;143(8):e254-e743. doi:10.1161/CIR.0000000000000950
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140(11):e563-e595. doi:10.1161/CIR.0000000000000677

4. Baart SJ, Dam V, Scheres LJJ, et al. Cardiovascular risk prediction models for women in the general population: a systematic review. *PLoS One*. 2019;14(1):e0210329. doi:10.1371/journal.pone.0210329
5. Markovitz AR, Stuart JJ, Horn J, et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. *Eur Heart J*. 2019;40(14):1113-1120. doi:10.1093/eurheartj/ehy863
6. Parikh NI, Jeppson RP, Berger JS, et al. Reproductive risk factors and coronary heart disease in the women's health initiative observational study. *Circulation*. 2016;133(22):2149-2158. doi:10.1161/CIRCULATIONAHA.115.017854
7. Adelborg K, Szepliget SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. *BMJ*. 2018;360:k96. doi:10.1136/bmj.k96
8. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. *BMJ*. 2016;353:i2610. doi:10.1136/bmj.i2610
9. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med*. 2012;366(24):2257-2266. doi:10.1056/NEJMoa1111840
10. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2009;339:b3914. doi:10.1136/bmj.b3914
11. Li M, Fan YL, Tang ZY, Cheng XS. Schizophrenia and risk of stroke: a meta-analysis of cohort studies. *Int J Cardiol*. 2014;173(3):588-590. doi:10.1016/j.ijcard.2014.03.101
12. Peters S, Carcel C, Millett E, Woodward M. Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study. *Neurology*. 2020;95(20):e2715-e2726. doi:10.1212/WNL.00000000000010982
13. Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. *Stroke*. 2007;38(1):16-21. doi:10.1161/01.STR.00000251695.39877.ca
14. Seifert CL, Poppert H, Sander D, et al. Depressive symptoms and the risk of ischemic stroke in the elderly: influence of age and sex. *PLoS One*. 2012;7(11):e50803. doi:10.1371/journal.pone.0050803
15. Kuiper JG, Bakker M, Penning-van Beest FJA, Herings RMC. Existing data sources for clinical epidemiology: the PHARMO database network. *Clin Epidemiol*. 2020;12:415-422. doi:10.2147/CLEP.S247575
16. Lamberts H, Wood M. *International Classification of Primary Care (ICPC)*. Oxford University Press; 1987.
17. WHO. *ATC Index With DDDs*. Collaborating Centre for Drug Statistics Methodology; 2002.
18. Beaulieu-Jones BK, Lavage DR, Snyder JW, Moore JH, Pendergrass SA, Bauer CR. Characterizing and managing missing structured data in electronic health records: data analysis. *JMIR Med Inform*. 2018;6(1):e11. doi:10.2196/medinform.8960
19. Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. *Atherosclerosis*. 2015;241(1):211-218. doi:10.1016/j.atherosclerosis.2015.01.027
20. Poorthuis MH, Algra AM, Algra A, Kappelle LJ, Klijn CJ. Female- and male-specific risk factors for stroke: a systematic review and meta-analysis. *JAMA Neurol*. 2017;74(1):75-81. doi:10.1001/jamaneurol.2016.3482
21. Zhou Y, Wang X, Jiang Y, et al. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. *Gynecol Endocrinol*. 2017;33(12):904-910. doi:10.1080/09513590.2017.1347779
22. Wiksten-Almströmer M, Hirschberg AL, Hagenfeldt K. Menstrual disorders and associated factors among adolescent girls visiting a youth clinic. *Acta Obstet Gynecol Scand*. 2007;86(1):65-72.
23. Sociaal Cultureel Planbureau Nssbph. Accessed June 24, 2021. scp.nl/Onderzoek/Lopend_onderzoek/A_z_allopende_onderzoeken/Statusscores.
24. Kurth T, Schurks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. *BMJ*. 2008;337:a636. doi:10.1136/bmj.a636
25. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335:974. doi:10.1136/bmj.39335.385301.BE
26. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15(4):361-387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
27. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106
28. Cooney MT, Vartiainen E, Laatikainen T, et al. Cardiovascular risk age: concepts and practicalities. *Heart*. 2012;98(12):941-946. doi:10.1136/heartjnl-2011-301478
29. Timpka S, Fraser A, Schyman T, et al. The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. *Eur J Epidemiol*. 2018;33(10):1003-1010. doi:10.1007/s10654-018-0429-1
30. Roeters van Lennep JE, Heida KY, Bots ML, Hoek A; collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2016;23(3):178-186. doi:10.1177/2047487314556004
31. Spasoff RA. *Epidemiologic Methods for Health Policy*. Oxford University Press; 1999.
32. Goldstein BA, Navar AM, Pencina MJ, Ioannidis JP. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. *J Am Med Inform Assoc*. 2017;24(1):198-208. doi:10.1093/jamia/ocw042
33. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. *Neurology*. 1999;53(3):537-542. doi:10.1212/wnl.53.3.537
34. Nielen MMJ, van der Meer V, Schellevis FG. *Evaluatie pilot PreventieConsult cardiometabolisch risico [Report in Dutch]*. NIVEL; 2010. Accessed March 4, 2021. nivel.nl/pdf/Rapport-Evaluatie-pilot-PreventieConsult.pdf.
35. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. *Neurology*. 2002;58(6):885-894. doi:10.1212/wnl.58.6.885
36. SCORE Working Group. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J*. 2021;42(25):2439-2454. doi:10.1093/eurheartj/ehab309
37. Lip GY, Nieuwlaar R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263-272. doi:10.1378/chest.09-1584
38. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21(1):128-138. doi:10.1097/EDE.0b013e3181c30fb2
39. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. *BMJ Open*. 2018;8(3):e020498. doi:10.1136/bmjopen-2017-020498
40. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. *BMJ*. 2016;353:i2416. doi:10.1136/bmj.i2416
41. Oertelt-Prigione S, Seeland U, Kendel F, et al. Cardiovascular risk factor distribution and subjective risk estimation in urban women: the BEFRI study: a randomized cross-sectional study. *BMC Med*. 2015;13:52. doi:10.1186/s12916-015-0304-9
42. Graham IM, Di Angelantonio E, Visseren F, et al. Systematic coronary risk evaluation (SCORE): JACC focus seminar 4/8. *J Am Coll Cardiol*. 2021;77(24):3046-3057. doi:10.1016/j.jacc.2021.04.052
43. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. *Lancet Neurol*. 2007;6(12):1106-1114. doi:10.1016/S1474-4422(07)70291-0
44. Ghossein-Doha C, Spaanderman M, van Kuijk SM, Kroon AA, Delhaas T, Peeters L. Long-term risk to develop hypertension in women with former preeclampsia: a longitudinal pilot study. *Reprod Sci*. 2014;21(7):846-853. doi:10.1177/1933719113518989